Aurobindo Pharma has reported results for fourth quarter and year ended March 31, 2022.
The company has reported a fall of 8.07% in its net profit at Rs 802.16 crore for the quarter under review as compared to Rs 872.58 crore for the same quarter in the previous year. Total income of the company decreased by 24.67% at Rs 3,300.54 crore for Q4FY22 as compared Rs 4,381.45 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a fall of 28.09% in its net profit at Rs 576.14 crore for the quarter under review as compared to Rs 801.18 crore for the same quarter in the previous year. Total income of the company decreased by 3.64% at Rs 5,858.25 crore for Q4FY22 as compared Rs 6,079.60 crore for the corresponding quarter previous year.
For the year ended March 31, 2022, the company has reported a fall of 53.27% in its net profit at Rs 1,454.71 crore as compared to Rs 3112.91 crore for the previous year. Total income of the company decreased by 27.14% at Rs 11,958.13 crore for year under review as compared to Rs 16,413.54 crore for year ended March 31, 2021.
For the year ended March 31, 2022, on the consolidated basis, the company has reported a fall of 50.37% in its net profit at Rs 2,647.11 crore as compared to Rs 5,333.82 crore for the previous year. Total income of the company decreased by 5.48% at Rs 23,775.84 crore for year under review as compared to Rs 25,155.47 crore for year ended March 31, 2021.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1858.70 |
Dr. Reddys Lab | 1258.55 |
Cipla | 1559.20 |
Lupin | 2198.25 |
Zydus Lifesciences | 1004.00 |
View more.. |